Legal Framework in India

Under the Drugs and Cosmetics Rules, 1945, and the applicable New Drugs and Clinical Trials Rules, 2019, pharmaceutical manufacturers and marketing authorisation holders must maintain pharmacovigilance systems and comply with applicable adverse drug reaction (ADR) reporting requirements. CDSCO guidance specifies 15-day expedited reporting for specified serious adverse reactions, including serious ADRs occurring in India and serious unexpected ADRs occurring outside India, where applicable.

CDSCO

+1

Potential consequences of delayed reporting include:

Regulatory action: Authorities may inspect records, require corrective measures, and take licensing action where a regulatory breach is established.

Financial or criminal penalties: These depend on the particular statutory provision violated and its prescribed punishment. Delay alone does not automatically attract a single universal fine or imprisonment term.

Civil liability: If delayed reporting contributes to preventable injury and the legal requirements are met, affected patients may pursue appropriate remedies.

Corrective action: Companies may need to investigate the delay, submit overdue reports, strengthen safety-monitoring procedures, and revise internal reporting systems.

The Pharmacovigilance Programme of India (PvPI) encourages reporting suspected adverse drug reactions, including serious and previously unknown reactions, to improve medicine safety.

Indian Patent Office

+1

Important Case Laws

1. Wyeth v. Levine, 555 U.S. 555 (2009)

The US Supreme Court considered whether federal drug regulation pre-empted a state-law failure-to-warn claim against a pharmaceutical manufacturer. The Court allowed the state-law claim to proceed on the facts before it. Although this was not a case about delayed pharmacovigilance reporting, it illustrates the potential legal consequences of inadequate drug-safety warnings and the importance of communicating material safety information.

2. Jacob Mathew v. State of Punjab, (2005) 6 SCC 1

The Supreme Court of India examined the standards governing criminal liability for medical negligence. It emphasised that criminal negligence requires a sufficiently high degree of negligence, rather than a mere error of judgment. By analogy, delayed safety reporting should not automatically be treated as a criminal offence without examining the applicable statutory duty, evidence, and required elements of liability.

3. Indian Medical Association v. V.P. Shantha, (1995) 6 SCC 651

The Supreme Court clarified the application of consumer-protection law to medical services. While the case did not concern pharmacovigilance reporting, it provides context for patient remedies where deficient healthcare causes legally recognised harm. A claim against a pharmaceutical company would still require proof of the relevant legal grounds.

Conclusion

Penalties for delayed pharmacovigilance reporting depend on the applicable reporting obligation, the seriousness and duration of the delay, the conduct of the responsible organisation, and the consequences for patients. Companies should promptly document, assess, and report qualifying adverse reactions, maintain audit trails, and correct reporting failures. The cited cases provide analogous principles; they do not establish a standalone judicial penalty specifically for delayed pharmacovigilance reporting.